Effects of Switching to Electronic Cigarettes with and without Concurrent Smoking on Exposure to Nicotine, Carbon Monoxide, and Acrolein
Open Access
- 1 September 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (9), 873-878
- https://doi.org/10.1158/1940-6207.capr-15-0058
Abstract
Concern has been raised about the presence of toxicants in electronic cigarette (EC) aerosol, particularly carbonyl compounds (e.g., acrolein) that can be produced by heating glycerol and glycols used in e-liquids. We investigated exposure to carbon monoxide (CO), nicotine (by measuring cotinine in urine), and to acrolein (by measuring its primary metabolite, S-(3-hydroxypropyl)mercapturic acid (3-HPMA) in urine) before and after 4 weeks of EC (green smoke, a “cig-a-like” EC, labeled 2.4% nicotine by volume) use, in 40 smokers. Thirty-three participants were using EC at 4 weeks after quitting, 16 (48%) were abstinent (CO-validated) from smoking during the previous week (EC only users), and 17 (52%) were “dual users.” A significant reduction in CO was observed in EC-only users [–12 ppm, 95% confidence interval (CI), –16 to –7, 80% decrease) and dual users (–12 ppm, 95%CI, –19 to –6, 52% decrease). Cotinine levels also declined, but to a lesser extent (EC-only users: –184 ng/mg creatinine; 95% CI, –733 to –365, 17% decrease; and dual users: –976 ng/mg creatinine; 95%CI, –1,682 to –270, 44% decrease). Mean 3-HPMA levels had decreased at 4 weeks by 1,280 ng/mg creatinine (95%CI, –1,699 to –861, 79% decrease) in EC-only users and by 1,474 ng/mg creatinine (95%CI, –2,101 to –847, 60% decrease) in dual users. In dual users, EC use significantly reduced exposure to CO and acrolein because of a reduction in smoke intake. EC may reduce harm even in smokers who continue to smoke, but long-term follow-up studies are needed to confirm this. Cancer Prev Res; 8(9); 873–8. ©2015 AACR.Keywords
This publication has 22 references indexed in Scilit:
- Was the Expansion of the Marketing License for Nicotine Replacement Therapy in the United Kingdom to Include Smoking Reduction Associated With Changes in Use and Incidence of Quit Attempts?Nicotine & Tobacco Research, 2013
- Levels of selected carcinogens and toxicants in vapour from electronic cigarettesTobacco Control, 2013
- Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot StudyInternational Journal of Environmental Research and Public Health, 2013
- Acrolein effects in pulmonary cells: relevance to chronic obstructive pulmonary diseaseAnnals of the New York Academy of Sciences, 2012
- Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokersCarcinogenesis: Integrative Cancer Research, 2012
- Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot studyBMC Public Health, 2011
- Acrolein – a pulmonary hazardMolecular Nutrition & Food Research, 2011
- Acrolein‐mediated injury in nervous system trauma and diseasesMolecular Nutrition & Food Research, 2011
- Effects of Smoking Cessation on Eight Urinary Tobacco Carcinogen and Toxicant BiomarkersChemical Research in Toxicology, 2009
- Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and diseaseMolecular Nutrition & Food Research, 2008